
5th Edition

Body MR Imaging, MR Angiography, and Central Nervous System (CNS) MR Imaging
Suggested 1.5T and 3T Protocols for various scanner vendors

- GE Healthcare MR Protocols
- Philips Healthcare MR Protocols
- Siemens Healthcare MR Protocols

This activity is jointly provided by:

This activity is supported by an educational grant from Bracco Diagnostics Inc.

Images courtesy of Asim K. Bag, MD, David S. Enterline, MD, FACR, Jeffrey H. Maki, MD, PhD, and Puneet Sharma, PhD.

Thomas M. Grist, MD, FACR
John Juhl Professor of Radiology,
Medical Physics, and Biomedical Engineering
University of Wisconsin School of Medicine
and Public Health
Chair, Department of Radiology
Radiology Clinic
University Wisconsin Hospital
Madison, Wisconsin
# TABLE OF CONTENTS

## Program Overview

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>Statement of Need</td>
<td>1</td>
</tr>
<tr>
<td>Target Audience</td>
<td>2</td>
</tr>
<tr>
<td>Learning Goal/Purpose</td>
<td>2</td>
</tr>
<tr>
<td>Educational Objectives</td>
<td>2</td>
</tr>
<tr>
<td>Accreditation Information</td>
<td>2</td>
</tr>
<tr>
<td>Instructions for Receiving Continuing Education (CE/CME) Credit</td>
<td>3</td>
</tr>
<tr>
<td>Disclosure of Conflicts of Interest</td>
<td>3</td>
</tr>
</tbody>
</table>


1. Gadolinium-based Contrast Agents .............................................................. 4
   A. Physicochemical Properties .................................................................... 4
      i. Concentration vs Relaxivity .......................................................... 7
      ii. Patient-Centric Care .................................................................... 8
   B. General Considerations ......................................................................... 8
      i. Body Weight and Contrast Dosing ............................................... 9
      ii. Contrast Variables (eg, Relaxivity, Timing, Injection Flow Rate, Scan Delay, Saline Flush) .......................................................... 10
      iii. Effect of Static Magnetic Field Strength .................................. 11
      iv. Patient Preparation .................................................................... 11
   C. Special Considerations ......................................................................... 12
      i. Prior Contrast/GBCA Reactions .................................................. 12
      ii. Patients with Asthma, Allergic Respiratory Disorders, and Prior Reactions to Iodinated Contrast Agents ............................................ 12
      iii. Nephrogenic Systemic Fibrosis ................................................ 13
      iv. Spurious Hypocalcemia ................................................................ 15
      v. Gadolinium Retention .................................................................... 15
      vi. High-risk Populations .................................................................. 16
   D. Immediate Adverse Events .................................................................... 17
      i. Treating Reactions to Contrast Agents ........................................ 18
2. MR Safety .................................................................................................. 19
3. Patient Screening .................................................................................... 21
4. Conclusions ................................................................................................ 21
5. References .................................................................................................. 23
PROGRAM OVERVIEW

INTRODUCTION
Recent innovations in magnetic resonance (MR) imaging hardware (high-field strength systems, faster gradients, improved radiofrequency [RF] transmit and receive coils) and the emergence of novel imaging acquisition sequences and protocols (eg, parallel imaging and compressed sensing) have greatly evolved the field of MR imaging. In conjunction with advances in MR imaging technology, there has been the arrival of novel gadolinium-based contrast agents (GBCAs) with different and improved properties compared with the original GBCAs. A high-relaxivity agent in combination with modern MR technology can improve examination efficiency in terms of time, expense, and patient management while reducing exposure to gadolinium. More importantly, these advances permit better visualization and assessment of pathological conditions and processes. Newer contrast agents, when combined with state-of-the-art acquisition protocols, provide the leeway to use lower doses for certain applications, a potential benefit in terms of patient safety.

The goals of this series about MR imaging protocols are to:

• Offer protocols that are state-of-the-art for newer equipment and contrast agents to enable clinicians to use MR imaging technologies to their fullest capabilities

• Provide an important educational service to radiologists and radiologic technologists (RTs) by presenting optimized approaches for the acquisition of highly diagnostic images of the central nervous system (CNS), body, and vasculature using newer-generation MR scanners, sequences, and acquisition parameters

• Demonstrate how protocols should be modified to take into account the different physicochemical properties of the currently available MR contrast agents

MR protocols that optimize image quality and maximize diagnostic performance while taking into account new technology and advances in GBCAs will greatly benefit the radiology community. This educational activity describes the latest developments in contrast media as they are used for CNS, MR angiography, and body MR imaging. The MR imaging protocols created for this course provide important considerations to take into account when moving between different field-strength magnets (1.5T-3T), and from conventional GBCAs to those with higher relaxivity or those that have been developed for targeted applications. Patient safety considerations and the needs of specialty populations, eg, patients with impaired renal function, are also discussed.

This activity contains suggested protocols specific to General Electric (GE), Siemens, and Philips MR systems, and was developed based on the consensus of 3 panels of experts with experience on each platform.

STATEMENT OF NEED

• Recent advances in magnetic resonance (MR) imaging and MR angiography technology have greatly improved the utility of this important noninvasive diagnostic modality for detecting lesions, staging disease progression, and guiding biopsies and surgical procedures in the settings of cardiovascular imaging, neuroradiology, and imaging of the body. These improvements include higher field strength magnets, dedicated coils, innovative pulse sequences, high-relaxivity contrast agents, and improved protocols. In order to take advantage of these advances, radiologists, radiologic technologists (RTs), and radiology nurses require education that enhances their understanding of these improved MR technologies

• Necessary education is not conveniently accessible on the subject of MR safety, including nephrogenic system fibrosis (NSF), acute adverse reactions to contrast media, and gadolinium retention, and until recently was not part of the core curriculum in the training of radiologists, RTs, and radiology nurses. Much of the information that does exist does not provide readily available implementation skills to avoid unnecessary adverse outcomes
TARGET AUDIENCE
The intended audience for this activity includes general and subspecialty radiologists, radiation oncologists, radiologic technologists, and radiology nurses.

LEARNING GOAL/PURPOSE
Provide radiologists, RTs, radiology nurses, and other healthcare providers involved with MRI with protocols/sequences that can help optimize imaging on GE, Philips, and Siemens scanners, while enhancing patient safety.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants will be able to:

• Describe 1.5T and 3T MR protocols that provide optimal visualization of difficult-to-identify abnormalities and lesions
• Review where and when gadolinium-based contrast agents (GBCAs) including high-relaxivity agents are most appropriate in terms of visualization of lesions and/or reducing the incidence of contrast-related adverse events
• Discuss possible acute and chronic adverse reactions to GBCAs including anaphylactoid reactions, nephrogenic systemic fibrosis (NSF), and gadolinium retention

ACCREDITATION INFORMATION

Physician Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and ABC Medical Education LLC. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Accreditation
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 0.5 contact hour of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 0.5 contact hour.

Radiologic Technologists
This activity is approved by the American Society of Radiologic Technologists (ASRT) for 1 Category A CE Credit. The ASRT is recognized by the American Registry of Radiologic Technologists as a Recognized Continuing Education Evaluation Mechanism. The ASRT had no involvement in the development of this activity.
INSTRUCTIONS FOR RECEIVING CONTINUING EDUCATION (CE/CME) CREDIT

Physicians and Nurses
Original Release Date: April 2012
Re-review Date: May 2018
Expiration Date: May 2020
Instructions to receive 0.5 AMA PRA Category 1 Credit™ or 0.5 ANCC Contact Hour
- Click on Physicians_and_Nurses_Credit to complete the activity evaluation and posttest questionnaire
- A statement of credit will be issued only upon receipt of a completed activity evaluation and a completed posttest with a score of 70% or better
- A statement of credit will be issued upon completion via e-mail

Radiologic Technologists
Release Date: May 21, 2018
Valid Through: June 1, 2020
Instructions to receive 1 Category A CE Credit
- Review activity in its entirety
- Click on CE_Credit to access posttest
- A statement of credit will be issued only upon receipt of a completed posttest with a score of 75% or better. A statement of credit will be issued upon completion via e-mail

DISCLOSURE OF CONFLICTS OF INTEREST
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

<table>
<thead>
<tr>
<th>Faculty</th>
<th>Reported Financial Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thomas M. Grist, MD, FACR</td>
<td>Grant/research support to UW School of Medicine and Public Health from GE HealthCare and Bracco Diagnostics Inc.</td>
</tr>
</tbody>
</table>

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:

<table>
<thead>
<tr>
<th>Content Manager</th>
<th>Reported Financial Relationship</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andy Galler (ABC Medical Education)</td>
<td>No financial relationships to disclose.</td>
</tr>
<tr>
<td>Medical Education Resources</td>
<td>No financial relationships to disclose.</td>
</tr>
</tbody>
</table>
1. GADOLINIUM-BASED CONTRAST AGENTS

A. Physicochemical Properties

At present, 8 gadolinium-based contrast agents (GBCAs) are approved by the US Food and Drug Administration (FDA) for use with magnetic resonance imaging (MRI), including (in order of FDA approval) Magnevist® (gadopentetate dimeglumine), ProHance® (gadoteridol), Omniscan™ (gadodiamide), OptiMARK™ (gadoversetamide), MultiHance® (gadobenate dimeglumine), Eovist® (gadoxetate disodium), Gadavist™ (gadobutrol), and Dotarem® (gadoterate meglumine).1–8 All of these agents cause T1 shortening based on the presence of a paramagnetic gadolinium (Gd³⁺) ion. However, each agent contains the Gd complexed with a chelate, and the chelates differ in terms of their molecular structures and physicochemical properties, both of which contribute to the safety and efficacy of the resulting contrast agent (Figure 1; Table 1).1–11 Ablavar® (gadofosveset trisodium), a high-relaxivity blood pool agent, was voluntarily withdrawn from the market by its manufacturer in 2016.

Table 1. Properties of MRI GBCAs1–9

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>FDA approval (United States)</th>
<th>Molarity (M)</th>
<th>Chemical structure</th>
<th>Ionicity</th>
<th>Protein binding</th>
<th>Combined Extracellular/ Hepatobiliary Agent</th>
<th>Hepatobiliary Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnevist</td>
<td>Gadopentetate dimeglumine</td>
<td>1988</td>
<td>0.5</td>
<td>Linear</td>
<td>Ionic</td>
<td>None</td>
<td>Extracellular Agents</td>
<td></td>
</tr>
<tr>
<td>Omniscan</td>
<td>Gadodiamide</td>
<td>1993</td>
<td>0.5</td>
<td>Linear</td>
<td>Nonionic</td>
<td>None</td>
<td>Extracellular Agents</td>
<td></td>
</tr>
<tr>
<td>OptiMARK</td>
<td>Gadoversetamide</td>
<td>1999</td>
<td>0.5</td>
<td>Linear</td>
<td>Nonionic</td>
<td>None</td>
<td>Extracellular Agents</td>
<td></td>
</tr>
<tr>
<td>ProHance</td>
<td>Gadoteridol</td>
<td>1992</td>
<td>0.5</td>
<td>Linear</td>
<td>Nonionic</td>
<td>None</td>
<td>Extracellular Agents</td>
<td></td>
</tr>
<tr>
<td>Gadavist</td>
<td>Gadobutrol</td>
<td>2011</td>
<td>1.0</td>
<td>Macrocyclic</td>
<td>Nonionic</td>
<td>None</td>
<td>Extracellular Agents</td>
<td></td>
</tr>
<tr>
<td>Dotarem</td>
<td>Gadobenate dimeglumine</td>
<td>2013</td>
<td>0.5</td>
<td>Macrocyclic</td>
<td>Nonionic</td>
<td>None</td>
<td>Extracellular Agents</td>
<td></td>
</tr>
<tr>
<td>MultiHance</td>
<td>Gadobenate dimeglumine</td>
<td>2004</td>
<td>0.5</td>
<td>Linear</td>
<td>Ionic</td>
<td>None</td>
<td>Extracellular Agent</td>
<td></td>
</tr>
<tr>
<td>Eovist</td>
<td>Gadoxetate disodium</td>
<td>2004</td>
<td>0.5</td>
<td>Linear</td>
<td>Ionic</td>
<td>None</td>
<td>Extracellular Agent</td>
<td></td>
</tr>
</tbody>
</table>

| FDA = US Food and Drug Administration; GBCAs = gadolinium-based contrast agents; MRI = magnetic resonance imaging. |
| ^r1 measured in plasma/serum at 37° to 40°C. |

Magnevist (gadopentetate dimeglumine), MultiHance (gadobenate dimeglumine), and Eovist (gadoxetate disodium) are open chain, linear, ionic agents, whereas Omniscan (gadodiamide) and OptiMARK (gadoversetamide) are linear, nonionic agents. MultiHance (gadobenate dimeglumine) is chemically similar to Magnevist (gadopentetate dimeglumine), but differs with the presence of a lipophilic benzylxoxymethyl side chain that extends from the chelate molecule. ProHance (gadoteridol), Gadavist (gadobutrol), and Dotarem (gadoterate meglumine) are macrocyclic in structure, with Dotarem (gadoterate meglumine) being the only ionic agent in this family. Most agents are formulated at a standard 0.5M concentration; exceptions include Gadavist (gadobutrol; formulated at a double concentration of 1.0M), and Eovist (gadoxetate disodium; formulated at 0.25M). Despite formulation at a higher concentration, the approved dose of Gadavist (gadobutrol; 0.1 mmol/kg) provides the same amount of gadolinium as the approved dose of MultiHance (gadobenate dimeglumine) and the other extracellular fluid (ECF) agents (also 0.1 mmol/kg), only it does so in half the volume.5,7
Figure 1. Structural Formulas of Gadolinium-based Contrast Agents

**Open-chain Ionic**

- Eovist (gadoxetate disodium)
- Magnevist (gadopentetate dimeglumine)

**Linear Nonionic**

- Omniscan (gadodiamide)
- OptiMARK (gadoversetamide)

**Macro cyclic**

- ProHance (gadoteridol)
- Gadavist (gadobutrol)
- Dotarem (gadoterate meglumine)
The 6 nonprotein-binding ECF agents—Magnevist (gadopentetate dimeglumine), ProHance (gadoteridol), Omniscan (gadodiamide), OptiMARK (gadoversetamide), Gadavist (gadobutrol), and Dotarem (gadoterate meglumine)—based on their physicochemical properties, have central nervous system (CNS) indications.\textsuperscript{1,6,9–11} The approved indication for Eovist (gadoxetate disodium) is consistent with its physicochemical properties, too; it is approved for liver imaging.\textsuperscript{12,13} MultiHance (gadobenate dimeglumine), which was originally approved in 2004 for use in CNS imaging, was granted FDA approval (July 2012) for use during MRA to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease\textsuperscript{14} (Table 2).

### Table 2. Currently Available Gadolinium-based Magnetic Resonance Contrast Agents\textsuperscript{1–8}

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Company</th>
<th>Indications</th>
<th>Approved Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnevist</td>
<td>Gadopentetate dimeglumine</td>
<td>Bayer Healthcare</td>
<td>CNS, adults &amp; pediatrics (≥2 years of age); Head &amp; neck, adults; Body (excluding the heart), adults &amp; pediatrics (≥2 years of age)</td>
<td>0.1 mmol/kg</td>
</tr>
<tr>
<td>ProHance</td>
<td>Gadoteridol</td>
<td>Bracco Diagnostics</td>
<td>CNS, adults &amp; pediatrics (&gt;2 years of age); Head and neck, adults</td>
<td>Adults: 0.1 mmol/kg + 2nd dose of 0.2 mmol/kg up to 30 min after 1st dose; pediatrics: 0.1 mmol/kg</td>
</tr>
<tr>
<td>Omniscan</td>
<td>Gadodiamide</td>
<td>GE Healthcare</td>
<td>CNS, adults &amp; pediatrics (2-16 years of age); Body (excluding the heart), adults &amp; pediatrics (2-16 years of age)</td>
<td>0.1 mmol/kg</td>
</tr>
<tr>
<td>OptiMARK</td>
<td>Gadoversetamide</td>
<td>Covidien</td>
<td>CNS, adults; Liver, adults</td>
<td>0.1 mmol/kg</td>
</tr>
<tr>
<td>Gadavist</td>
<td>Gadobutrol</td>
<td>Bayer Healthcare</td>
<td>CNS, adults &amp; pediatrics (including term neonates); Assess presence and extent of malignant breast disease; MRA to evaluate known or suspected supra-aortic or renal artery disease in adult and pediatrics (including term neonates)</td>
<td>0.1 mmol/kg</td>
</tr>
<tr>
<td>Dotarem</td>
<td>Gadoterate meglumine</td>
<td>Guerbet</td>
<td>CNS, adults &amp; pediatrics (including term neonates)</td>
<td>0.1 mmol/kg</td>
</tr>
<tr>
<td>MultiHance</td>
<td>Gadobenate dimeglumine</td>
<td>Bracco Diagnostics</td>
<td>CNS, adults &amp; pediatrics (including term neonates); MRA in adults, to evaluate known or suspected renal or aorto-ilio-femoral occlusive vascular disease</td>
<td>Adults &amp; pediatrics ≥2 years of age: 0.1 mmol/kg; pediatrics &lt;2 years of age: 0.05-0.1 mmol/kg (ie, 0.1-0.2 mL/kg) (CNS)</td>
</tr>
<tr>
<td>Eovist</td>
<td>Gadoxetate disodium</td>
<td>Bayer Healthcare</td>
<td>Liver imaging in adults</td>
<td>0.025 mmol/kg</td>
</tr>
</tbody>
</table>

CNS = central nervous system; MRA = magnetic resonance angiography.

In terms of biodistribution, most of the agents approved in the United States (with the exception of MultiHance [gadobenate dimeglumine] and Eovist [gadoxetate disodium]) distribute solely to the ECF space and are eliminated almost exclusively by glomerular filtration via the kidneys. MultiHance (gadobenate dimeglumine) differs in that 0.6% to 4% of the injected dose is excreted through the biliary tract.\textsuperscript{5} Thus, in addition to its use as an ECF agent, it is also suitable for delayed hepatobiliary phase imaging.\textsuperscript{15} The injected dose of Eovist (gadoxetate disodium) is eliminated from the kidneys and liver on a 50:50 basis; therefore, this agent is useful primarily as a liver-specific imaging agent.\textsuperscript{6}

All ECF GBCAs have an elimination half-life of approximately 1.5 hours; however, the half-lives of MultiHance (gadobenate dimeglumine) and Eovist (gadoxetate disodium) are 1.17±0.26 to 2.02±0.6 hours and 0.91 to 0.95 hours, respectively (Table 3).\textsuperscript{1–8}
i. Concentration vs Relaxivity

Unlike contrast-enhanced (CE) computed tomography (CT), which relies on contrast agent concentration in tissues, CE-MRI depends on contrast agent relaxivity and dose for achieving optimal enhancement.\textsuperscript{16} The higher the r1 relaxivity of an agent, the greater its ability to provide contrast enhancement. The r1 relaxivity values of the ECF-only “conventional” GBCAs (ie, Magnevist [gadopentetate dimeglumine], ProHance [gadoteridol], Omniscan [gadodiamide], OptiMARK [gadoversetamide], and Dotarem [gadoterate meglumine]) are very similar despite differences in molecular structure (see Table 1).\textsuperscript{9,12,14} Due to the presence of the lipophilic side chain, MultiHance (gadobenate dimeglumine) interacts with serum proteins, greatly increasing the apparent size of the molecule and reducing its tumbling rate.\textsuperscript{10} As a result, MultiHance (gadobenate dimeglumine) has almost twice the r1 and r2 relaxivity in plasma compared with the older ECF agents, and this higher relaxivity has been shown to persist at all commercially available magnetic field strengths (ie, 0.2T-3T) (Table 4).\textsuperscript{9,10,12,14}

Most importantly, higher relaxivity has been shown in parallel and intraindividual crossover studies to provide diagnostic benefit for a wide variety of clinical applications, including the CNS, breast and liver imaging, and MRA.\textsuperscript{17-31} Specifically, these studies show that MultiHance (gadobenate dimeglumine) generates greater signal enhancement at the same molar dose or equivalent signal enhancement at a lower dose.\textsuperscript{17-31} In addition, the greater r2 relaxivity of MultiHance (gadobenate dimeglumine) may have advantages for perfusion imaging and applications for which greater T2-weighting is required.\textsuperscript{32}

Table 3. Mean Elimination Half-life for Available GBCAs Agents\textsuperscript{1-8}

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Generic Name</th>
<th>Mean Elimination Half-life (Hours)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnevist</td>
<td>Gadopentetate dimeglumine</td>
<td>1.6 ± 0.13</td>
</tr>
<tr>
<td>ProHance</td>
<td>Gadoteridol</td>
<td>1.57 ± 0.08</td>
</tr>
<tr>
<td>Omniscan</td>
<td>Gadodiamide</td>
<td>1.3 ± 0.27</td>
</tr>
<tr>
<td>OptiMARK</td>
<td>Gadoversetamide</td>
<td>1.7 ± 0.33</td>
</tr>
<tr>
<td>Gadavist</td>
<td>Gadobutrol</td>
<td>1.81 (1.33 to 2.13)</td>
</tr>
<tr>
<td>Dotarem</td>
<td>Gadodotate meglumine</td>
<td>1.4 ± 0.2 to 2.0 ± 0.7</td>
</tr>
<tr>
<td>MultiHance</td>
<td>Gadobenate dimeglumine</td>
<td>1.17 ± 0.26 to 2.02 ± 0.60</td>
</tr>
<tr>
<td>Eovist</td>
<td>Gadoxetate disodium</td>
<td>0.91 to 0.95</td>
</tr>
</tbody>
</table>

GBCAs = gadolinium-based contrast agents.

Table 4. Relaxivities of MultiHance (gadobenate dimeglumine) vs Magnevist (gadopentetate dimeglumine) at Varying Magnetic Field Strengths\textsuperscript{9,10,12,14}

<table>
<thead>
<tr>
<th>Field Strength</th>
<th>r1 (L·mmol(^{-1})·sec(^{-1}))</th>
<th>r2 (L·mmol(^{-1})·sec(^{-1}))</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Magnevist (gadopentetate dimeglumine)</td>
<td>MultiHance (gadobenate dimeglumine)</td>
</tr>
<tr>
<td>0.2 T</td>
<td>5.7</td>
<td>10.9</td>
</tr>
<tr>
<td>0.47 T</td>
<td>3.8-4.9</td>
<td>9.2-9.7</td>
</tr>
<tr>
<td>1.5 T</td>
<td>3.9-4.1</td>
<td>6.3-7.9</td>
</tr>
<tr>
<td>3.0 T</td>
<td>3.7-3.9</td>
<td>5.5-5.9</td>
</tr>
</tbody>
</table>
The higher-concentration ECF agent Gadavist (gadobutrol) does not interact with serum proteins and, therefore, does not show the enhanced relaxivity in the presence of serum proteins seen with MultiHance (gadobenate dimeglumine). A slight increase in relaxivity over the conventional agents has been noted with Gadavist (gadobutrol); however, as demonstrated in a study in patients with brain metastases, Gadavist (gadobutrol) at 0.1 and 0.2 mmol/kg doses performs similarly to a 0.2 mmol/kg dose of the conventional ECF agent ProHance (gadoteridol). Most recently, equivalent 0.1 mmol/kg doses of MultiHance (gadobenate dimeglumine) and Gadavist (gadobutrol) were directly compared in an intraindividual crossover comparison for qualitative and quantitative evaluation of brain tumors in 114 adult patients. All 3 blinded readers demonstrated a significant preference for MultiHance (gadobenate dimeglumine) for all qualitative endpoints. In addition, significantly superior contrast-to-noise and lesion-to-brain ratios were observed with MultiHance (gadobenate dimeglumine). These studies demonstrate that, when administered at the same dose, a higher-concentration agent does not provide the same benefit for visualization of CNS lesions as a higher-relaxivity agent. Eovist (gadoxetate disodium) is formulated at lower concentration (0.25M) but does have a higher r1 relaxivity (6.9 L • mmol –1 • sec–1 at 1.5T) compared with conventional contrast agents. Eovist (gadoxetate disodium) has been approved for T1-weighted MRI of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

ii. Patient-Centric Care

Patient-centric care—is of growing importance in medicine. Not only are no 2 patients alike, but when medicine can be tailored to meet the specific needs of an individual patient, outcomes can be improved while containing healthcare expenditures and maximizing safety.

Recently, patient-centric dosing of ionizing radiation and iodinated contrast media has gained increasing attention within the radiology community. Customizing CT and CTA protocols to minimize exposure to ionizing radiation and/or lower contrast dose in susceptible patients has allowed radiologists to acquire diagnostically acceptable exams while maximizing patient safety. The use of patient-centric dosing has been facilitated by technologic and software advances in CT.

Likewise in MRI/MRA, advanced technology and software coupled with higher relaxivity and specialized GBCAs have paved the way for patient-centric dosing of contrast in MR imaging. Today we possess the ability to minimize patients’ exposure to gadolinium while providing examinations that can be life-saving. In many situations we can customize contrast dosing by selecting a specific agent and/or lowering the contrast dose, thereby minimizing gadolinium exposure. This approach is particularly important in patients with renal impairment, patients undergoing serial contrast-enhanced examinations, and in light of reports of gadolinium retention in brain and body tissues.

B. General Considerations

Understanding and determining how to make the best use of new hardware and contrast agent options can be challenging. This series of MR protocols for CNS, body MRI, and MRA has been assembled by consensus of an expert panel to aid in this process, with the goal of providing practical tips and specific protocols for each anatomic region for 3 MR scanner vendors: General Electric (GE), Philips, and Siemens Healthcare. In these protocols, attention has been given to specific recommended imaging parameters at 1.5T and 3T, but also to methods for preparing the patient, streamlining the exam, and making the best use of contrast material to maximize efficacy while ensuring patient safety.

General considerations in preparing patients for CE exams that are addressed in the MR protocols, where relevant, are as follows:
i. Body Weight and Contrast Dosing

Dosing of contrast should be based on patient body weight as described in the prescribing information for each contrast agent. With the exception of Eovist (gadoxetate disodium), standard dosing for all products is 0.1 mmol/kg body weight, although for MultiHance (gadobenate dimeglumine) in children <2 years of age, the recommended dose range is 0.05 to 0.1 mmol/kg (0.1-0.2 mL/kg). Among the approved agents, only ProHance (gadoteridol) is approved at doses >0.1 mmol/kg (up to 0.3 mmol/kg cumulative dose),2 and Eovist (gadoxetate disodium) is dosed at 0.025 mmol/kg. When selecting a contrast agent for liver imaging, there are dosing considerations: despite the higher relaxivity of Eovist (gadoxetate disodium), the approved dose is 4 times lower than MultiHance (gadobenate dimeglumine), resulting in a shorter peak arterial perfusion window; as a result, selection of an appropriate scan delay can be challenging.36,37 In order to overcome this, when using Eovist (gadoxetate disodium), clinicians may consider using a fixed delay, diluting the dose of bolus, or injecting at a slower rate. Additionally, in cases of cirrhotic liver, the use of a higher off-label dose of Eovist (gadoxetate disodium) may be required.36,37 Note that for Gadavist (gadobutrol), because it is the only agent available at a 1.0M concentration, care must be taken to halve the volume in order to deliver the same molar dose as agents formulated at 0.5M in order to prevent overdose.

The higher relaxivity of MultiHance (gadobenate dimeglumine) allows the option of using a standard dose for increased sensitivity in procedures where double or triple doses of other ECF agents may have been required to achieve satisfactory diagnostic results:

• CNS
  - The standard approved dose for CNS imaging using conventional 0.5M contrast agents and 1M Gadavist (gadobutrol) is 0.1 mmol/kg. However, higher doses of 0.2 or 0.3 mmol/kg are sometimes used for perfusion imaging, MRA, or certain brain protocols.2,38,39 For high-relaxivity agents such as MultiHance (gadobenate dimeglumine), a 0.1 mmol/kg dose is suggested. However, in patients with chronic kidney disease (CKD) at risk for nephrogenic systemic fibrosis (NSF), use of a lower dose of a high-relaxivity agent may be beneficial (see section on NSF below). The other high-relaxivity agent, Eovist (gadoxetate disodium), lacks a CNS indication.6

• Body MRI
  - For body MRI in general, the dose of GBCA administered depends on the type of agent and patient weight. Conventional contrast agents, as well as Gadavist (gadobutrol), should employ 0.1 mmol/kg body weight. The approved dose for Eovist (gadoxetate disodium) for liver imaging is 0.025 mmol/kg

• MRA
  - In clinical practice, MRA is often performed with a double dose of gadolinium contrast (0.2 mmol/kg). However, a single dose of MultiHance (gadobenate dimeglumine) has been shown to be equivalent to a double dose of Magnevist (gadopentetate dimeglumine) for renal MRA26 and carotid MRA40 at 1.5T. Additionally, at 3T, MultiHance (gadobenate dimeglumine) has been shown to significantly improve image quality and contrast enhancement compared to an equivalent 0.1 mmol/kg dose of Magnevist (gadopentetate dimeglumine)21
  - In a multicenter crossover comparison of 0.1 mmol/kg doses of MultiHance (gadobenate dimeglumine) and Magnevist (gadopentetate dimeglumine) for peripheral MRA, technical adequacy and diagnostic accuracy of CE-MRA were found to be significantly better with MultiHance (gadobenate dimeglumine) as compared with Magnevist (gadopentetate dimeglumine) (P<0.0001 and P≤0.0017, respectively).32 A recent crossover comparison study of peripheral artery disease demonstrated that the image quality and diagnostic performance achieved with 0.1 mmol/kg single-dose MultiHance (gadobenate dimeglumine) is at least equivalent to that achieved with 0.2 mmol/kg double-dose Magnevist (gadopentetate dimeglumine)31
In patients with known or suspected steno-occlusive disease of the supra-aortic vessel, a recent crossover comparison demonstrated that the image quality and diagnostic performance achieved with single-dose 0.1 mmol/kg MultiHance (gadobenate dimeglumine) is at least equivalent to that achieved with double-dose 0.2 mmol/kg Magnevist (gadopentetate dimeglumine). A comparison of the 1.0M agent Gadavist (gadobutrol) with MultiHance (gadobenate dimeglumine) for MRA of the lower extremities demonstrated that 0.1 mL/kg of both (ie, equivalent volumes) provided similar diagnostic results, despite the fact that using this dosing regimen, MultiHance (gadobenate dimeglumine) was given at half of the approved gadolinium dose. Similarly, for renal MRA, 15 mL of MultiHance (gadobenate dimeglumine) (0.1 mmol/kg) at 3T was found to be equivalent to 15 mL of Gadavist (gadobutrol) (0.2 mmol/kg) at 1.5T. The 1.0M formulation of Gadavist (gadobutrol) allows for a 50% reduced injection volume and it has been proposed that using this lower volume, one might expect a sharper peak in the contrast bolus. Comparative studies have produced conflicting results. Overall it seems that 1.0M Gadavist (gadobutrol) may be advantageous for MRA compared with conventional Gd contrast agents, depending on the vascular territory being investigated, but this benefit is not greater than the benefit of a higher-relaxivity agent for CE-MRA.

Specific protocol recommendations are available for review in the GE, Philips, and Siemens protocols chapters.

**ii. Contrast Variables (eg, Relaxivity, Timing, Injection Flow Rate, Scan Delay, Saline Flush)**

Different MR applications may require different techniques for administering contrast. With the exception of applications such as cerebral or cardiac perfusion, where injection rates may be as high as 4 to 5 mL/sec, a 22-gauge intravenous (IV) line in the antecubital fossa or distal forearm is sufficient. Other than MRA, most contrast-enhanced neurologic MR applications do not require precise contrast timing or flow rate, and many institutions administer the GBCA through a small “butterfly” needle by hand in place of an IV line. In such cases, administration of a saline flush is prudent but may not be absolutely necessary.

Body and MRA applications require more precise contrast timing. For visceral parenchymal imaging (ie, liver, kidney, pancreas), multiple dynamic three-dimensional (3D) datasets are acquired, and exact timing (particularly for the arterial phase) is essential. To capture the arterial phase accurately, many body MR protocols use a timing bolus, a bolus detection method (eg, bolus tracking), or a time-resolved technique (eg, multiple fast arterial phases without the need for any timing). Proper scan timing is then determined by beginning the scan so that data acquisition in the center of k-space coincides with the arterial contrast arrival. Such timing techniques are discussed in the protocols.

Many institutions find an automated contrast injector beneficial so that the patient can be connected to the injector at the beginning of the scan, and then the contrast and the saline flush can be administered easily and automatically from the magnet control room. In addition, power injectors allow more precise and reproducible injection rates, which are critical for avoiding variations between patients in the capture of the arterial phase. Furthermore, using power injectors facilitates the flow of the examination and saves time by eliminating the need for personnel to enter the MRI examination room to inject the contrast agent by hand. However, there are some exceptional situations for which hand injections can be used (eg, when venous access is unreliable and a direct visual control is needed during injection to ensure that extravasation is not occurring). Commercially available long tubing sets are preferred in those cases so that the patient does not need to be moved in and out of the magnet. The contrast is generally injected at approximately 2 mL/sec and followed by 20 to 30 mL normal saline (NS) injected at the same rate. If the test bolus technique is used to capture the arterial phase, we recommend the following:
- Conventional GBCAs: 2 mL at 2 mL/sec
- 1.0M Gadavist (gadobutrol): 1 mL at 2 mL/sec
- High-relaxivity MultiHance (gadobenate dimeglumine): 1 mL at 2 mL/sec
- Eovist (gadoxetate disodium): No test bolus; typically need to use multiphase MRI or a fluoroscopic trigger
- NS flush of 20 to 30 mL at 2 mL/sec

Contrast administration rate and timing are probably most critical for MRA. The general goal is to begin data acquisition (usually centric) precisely when intravascular contrast approaches peak concentration, and then acquire data during the “plateau” and “downslope” phases of contrast passage, ending before it is completely passed. In some applications, such as carotid and peripheral MRA, data acquisition may be much longer than the contrast bolus passage, depending on recirculation for continued enhancement. In general, MultiHance (gadobenate dimeglumine) can be administered at lower doses and slower flow rates than other ECF agents, and recommendations are given in the protocol section.

For MRA, the expert panel unanimously advocated use of a contrast injector to administer contrast and fluoroscopic triggering for bolus detection (the exception being some time-resolved protocols where multiple time frames are provided by the protocol). It is important to administer 20 to 30 mL NS flush at the same rate as the contrast administration in order to “push” the contrast completely through the veins and into the right side of the heart so that the contrast bolus stays intact. Due to the higher concentration and potentially more compact bolus of Gadavist (gadobutrol), care must be taken to ensure the contrast peak is not missed when using this product. Alternatively, a dilution of Gadavist (gadobutrol) in saline to a concentration of 0.5M or lower can be used.

Certain applications may benefit by dilution of any contrast agent into a volume of saline. For example, investigators have shown that the diluted contrast approach may be beneficial in circumstances where there is less mixing of the contrast agent with blood, including in the pulmonary arteries. Likewise, dilution may be beneficial when the R2 relaxivity associated with high arterial concentrations of GBCA may create signal loss at peak arterial concentrations. These situations may be encountered with high rates of injection, at high field strengths (3T), and in situations where there is little mixing or dispersion of the GBCA in blood.

iii. Effect of Static Magnetic Field Strength

The higher signal and quality gradient coils at 3T have great potential. In general, a smaller number of excitations, or averages, are needed for higher-resolution images. The increased r1 and r2 relaxivities of MultiHance (gadobenate dimeglumine) compared with other GBCAs persist at all clinically relevant field strengths tested (0.2T, 0.47T, 1.5T, and 3T) (see Table 4). Higher relaxivity correlates with shorter tissue T1 and T2 relaxation times when comparing conventional agents and MultiHance (gadobenate dimeglumine). In practice, these data translate into more robust T1 enhancement (or greater T2 signal loss for susceptibility-weighted imaging) for MultiHance (gadobenate dimeglumine) compared with other GBCAs on a per-molar basis at any field strength. The improved contrast efficiency of MultiHance (gadobenate dimeglumine) means that equal contrast enhancement can be achieved at a lesser dose or that greater contrast enhancement is achieved at the same dose.

iv. Patient Preparation

The MR protocols attempt to describe details of the complete exam, including but not limited to patient positioning and preparation, coil type selection, and IV and electrocardiogram (ECG) requirements, where appropriate. Step-by-step pulse sequences and guidance on their implementation are also provided, along with details of GBCA dosing and administration.
C. Special Considerations

i. Prior Contrast/GBCA Reactions

According to the American College of Radiology (ACR) *Manual on Contrast Media*, patients with a prior reaction to a GBCA are up to 8 times more likely to experience a GBCA-related acute adverse event.\(^4\) The ACR guidelines suggest that in these cases, a different contrast agent be used the second time and those patients be premedicated with corticosteroids and antihistamines (Table 5).\(^4\) However, it is important to note that allergic reactions to GBCAs have been found to occur even in patients premedicated with corticosteroids or antihistamines.\(^4\)

The approved labeling for all GBCAs lists hypersensitivity as a contraindication or a warning/precaution; however, true allergic reactions occur infrequently, ranging from 0.004% to 0.7%.\(^4\) Moreover, hypersensitivity reactions are associated with patient immune system functionality and overall condition rather than the administered GBCA.\(^6\) With all GBCAs, the prescribing information suggests closely monitoring patients for hypersensitivity reactions during administration and, where specified, from up to 2 hours (MultiHance [gadobenate dimeglumine]) to several hours (Magnevist [gadopentetate dimeglumine], ProHance [gadoteridol], Omniscan [gadodiamide], OptiMARK [gadoversetamide]) following contrast administration.\(^1\)–\(^5\)

Table 5. Commonly Used Premedication Regimens for MRI\(^4\)

<table>
<thead>
<tr>
<th>Medication</th>
<th>Dose</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Option 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prednisone(^a)</td>
<td>50 mg PO</td>
<td>13 h, 7 h, and 1 h before injection of contrast medium</td>
</tr>
<tr>
<td>Plus diphenhydramine (Benadryl(^b))</td>
<td>50 mg IV, IM, or PO</td>
<td>1 h before injection of contrast medium</td>
</tr>
<tr>
<td><strong>Option 2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methylprednisolone(^b) (Medrol(^b))</td>
<td>32 mg PO</td>
<td>12 h and 2 h before injection of contrast medium</td>
</tr>
</tbody>
</table>

\(^a\)Hydrocortisone 200 mg IV may be substituted for oral prednisone.
\(^b\)An antihistamine may be added to this regimen, as in option 1.

ii. Patients with Asthma, Allergic Respiratory Disorders, and Prior Reactions to Iodinated Contrast Agents

Patients with asthma and allergies, as well as those with a previous reaction to an iodinated agent, should be monitored carefully because of their increased risk for experiencing adverse reactions. Patients in this subset have an increased likelihood of a reaction, with reaction rates reported as high as 3.7%.\(^4\)
III. Nephrogenic Systemic Fibrosis

Nephrogenic systemic fibrosis is a rare but potentially disabling and life-threatening scleroderma-like disorder affecting patients with reduced renal function. Almost all cases of NSF occurred in patients with CKD Stages 4 and 5 (glomerular filtration rate [GFR] < 30 mL/min/1.73 m²). However, several cases have been observed in patients with Stage 3 CKD (GFR 30–59 mL/min/1.73 m²) and in patients with acute renal failure. The association of NSF with exposure to GBCAs was made in 2006. Additional risk factors identified include repeated GBCA administration and/or use of high doses of contrast.

The exact pathophysiology of NSF is not well understood; however, several lines of evidence support a mechanism of transmetallation. Transmetallation involves the dissociation of gadolinium from its chelate and replacement with another ion. Free gadolinium ions, known to be toxic, would then be available to accumulate in the tissue, particularly in patients with poor renal function and, thus, longer elimination times. Among the different GBCAs, there are significant differences in measured stability (ie, conditional stability constants [thermodynamic stability constants measured at physiologic pH] and kinetic stabilities) (Table 6): the macrocyclic agents (ProHance [gadoteridol], Gadavist [gadobutrol], and Dotarem [gadoterate meglumine]) have the highest kinetic stabilities, followed by the linear ionic agents (Magnevist [gadopentetate dimeglumine], MultiHance [gadobenate dimeglumine], and Eovist [gadoxetate disodium]). The linear nonionic agents, Omniscan (gadodiamide) and OptiMARK (gadoversetamide), have the lowest kinetic stabilities. Based on the conditional stability constants, Omniscan (gadodiamide), OptiMARK (gadoversetamide), and Gadavist (gadobutrol) are the least stable. Regardless of the parameter used, it is believed that the less stable an agent, the more likely it is to be involved in the process of transmetallation. Consistent with this theory, the vast majority of NSF cases have occurred after administration of Omniscan (gadodiamide), followed by Magnevist (gadopentetate dimeglumine) and OptiMARK (gadoversetamide), with 99% of the unconfounded (single agent) cases occurring following administration of 1 of these 3 agents. Accordingly, in 2010, the FDA contraindicated all 3 of these agents in patients with severe CKD (ie, estimated GFR [eGFR] < 30 mL/min/1.73 m²) and/or acute renal injury.

Table 6. Stabilities of GBCAs

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Contrast Agent</th>
<th>Conditional Stability Constant at pH 7.4</th>
<th>Kinetic Stability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnevist</td>
<td>Gadopentetate dimeglumine</td>
<td>17.7</td>
<td>Low</td>
</tr>
<tr>
<td>Omniscan</td>
<td>Gadodiamide</td>
<td>14.9</td>
<td>Low</td>
</tr>
<tr>
<td>OptiMARK</td>
<td>Gadoversetamide</td>
<td>15.0</td>
<td>Low</td>
</tr>
<tr>
<td>MultiHance</td>
<td>Gadobenate dimeglumine</td>
<td>18.4</td>
<td>Medium</td>
</tr>
<tr>
<td>Eovist</td>
<td>Gadoxetate disodium</td>
<td>18.7</td>
<td>Medium</td>
</tr>
<tr>
<td>Dotarem</td>
<td>Gadoterate meglumine</td>
<td>19.3</td>
<td>High</td>
</tr>
<tr>
<td>ProHance</td>
<td>Gadoteridol</td>
<td>17.1</td>
<td>High</td>
</tr>
<tr>
<td>Gadavist</td>
<td>Gadobutrol</td>
<td>14.7</td>
<td>High</td>
</tr>
</tbody>
</table>

GBCAs = gadolinium-based contrast agents.
The ACR also recently modified its recommendations, stratifying the available GBCAs into categories according to NSF risk: Group I agents, or agents associated with the greatest number of NSF cases, include Omniscan (gadodiamide), OptiMARK (gadoversetamide), and Magnevist (gadopentetate dimeglumine); Group II agents, or agents associated with few, if any, NSF cases, include MultiHance (gadobenate dimeglumine), ProHance (gadoteridol), Dotarem (gadoterate meglumine), and Gadavist (gadobutrol); the Group III agent, Eovist (gadoxetate disodium), is of unknown risk because data remain limited, because Eovist (gadoxetate disodium) has not been available in the United States long enough for evaluation (Table 7).

**Table 7. NSF Risk Stratification for Available GBCAs**

<table>
<thead>
<tr>
<th>Brand Name</th>
<th>Contrast Agent</th>
<th>FDA Contraindication</th>
<th>ACR Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Magnevist</td>
<td>Gadopentetate dimeglumine (Gd-DTPA)</td>
<td>X</td>
<td>I</td>
</tr>
<tr>
<td>Omniscan</td>
<td>Gadodiamide (Gd-DTPA-BMA)</td>
<td>X</td>
<td>I</td>
</tr>
<tr>
<td>OptiMARK</td>
<td>Gadoversetamide (Gd-DTPA-BMEA)</td>
<td>X</td>
<td>I</td>
</tr>
<tr>
<td>ProHance</td>
<td>Gadoteridol (Gd-HP-DO3A)</td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>Gadavist</td>
<td>Gadobutrol (Gd-BT-DO3A)</td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>MultiHance</td>
<td>Gadobenate dimeglumine (Gd-BOPTA)</td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>Dotarem</td>
<td>Gadoterate meglumine (Gd-DOTA)</td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>Eovist</td>
<td>Gadoxetate disodium (Gd-EOB-DTPA)</td>
<td></td>
<td>III</td>
</tr>
</tbody>
</table>

ACR = American College of Radiology; FDA = Food and Drug Administration; GBCAs = gadolinium-based contrast agents; NSF = nephrogenic systemic fibrosis.

The following precautions to minimize the risk of NSF are recommended:

- High-risk patients should be identified (as mentioned above, eGFR <30 mL/min/1.73 m²), preferably by screening of renal function (especially in patients >60 years of age, with hypertension, diabetes, or severe hepatic disease)⁵¹
- Several guidelines, including those of the ACR⁵¹ have, until now, also accepted patients’ medical histories as valid screening tools. However, it is important to note that a significant number of patients with severe kidney disease may be unaware of their disease⁵²
• Patients at risk should be given the lowest possible dose of a Group II or Group III agent, and every effort should be made to minimize the accumulated dose over time. In addition, these patients should obtain a radiologist-signed order of consent, as well as give informed consent stating that they understand the risks and benefits of the procedure.

• Patients on hemodialysis should be scheduled for their contrast-enhanced imaging examination immediately prior to a scheduled hemodialysis session.

• An updated FDA Alert dated September 9, 2010, required the following Boxed Warning be included on all GBCA product labeling:

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
See full prescribing information for complete boxed warning
Gadolinium-based contrast agents (GBCAs) increase the risk of NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities.
- The risk for NSF appears highest among patients with:
  - chronic, severe kidney disease (GFR <30 mL/min/1.73m²), or
  - acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age >60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

It is important to note that prohibiting all GBCA use in patients with severe CKD is not always warranted since in these patients, the risk of developing NSF following exposure to a GBCA is estimated between 1% and 7%. Instead, a careful evaluation of the risks versus the benefits of a CE-MRI examination should be made and, if a decision to proceed with a CE exam is made, the use of an agent with a low associated NSF risk should be considered.

iv. Spurious Hypocalcemia

Omniscan (gadodiamide) and OptiMARK (gadoversetamide) – but not ProHance (gadoteridol), Magnevist (gadopentetate dimeglumine), Gadavist (gadobutrol), Eovist (gadoxetate disodium), Dotarem (gadoterate meglumine), or MultiHance (gadobenate dimeglumine) – interfere with the most common colorimetric assay for serum calcium, potentially leading to the erroneous diagnosis of hypocalcemia in patients who recently underwent routine MR examinations. Clinicians should be aware of this effect when evaluating serum calcium abnormalities in patients who have recently received Omniscan (gadodiamide) or OptiMARK (gadoversetamide).

v. Gadolinium Retention

During the past several years, multiple published studies have reported residual brightness in tissues within the deep nuclei of the brain in patients who have undergone repeat contrast-enhanced MRIs. These hyperintense areas are noted principally in the globus pallidus and the dentate nucleus. The persisting changes in signal brightness have been associated with the retention of gadolinium from GBCAs, and most of the patients cited in these reports have normal renal function. These findings have led to concerns about the long-term safety of GBCAs and raise the question as to whether gadolinium retention from GBCAs could be harmful. To date, no studies or substantiated case reports have demonstrated any adverse clinical effects in humans or mammals caused by gadolinium retention in the brain.
The question has been posed: Are linear GBCAs more prone to gadolinium retention than macrocyclic agents? The findings to date have been mixed; some studies demonstrate significantly higher odds for gadolinium retention to be caused by linear agents than macrocyclic agents, while other studies have not come to this conclusion. The International Society for Magnetic Resonance in Medicine (ISMRM) issued a position paper in 2017. The ISMRM supports the clinical importance of GBCAs for detecting disease and saving lives. In most instances, they consider the benefits of GBCA use to outweigh any potential risks of gadolinium retention. The ISMRM supports further research on determining the mechanism(s) of gadolinium retention. They note that some macrocyclic agents might deposit less gadolinium than some linear agents, but evidence demonstrates that gadolinium retention in the brain occurs after the administration of macrocyclic agents. Based on the available evidence, it must be noted that the extent of gadolinium retention varies not only among the individual GBCAs, but also among agents within the same structural class (ie, linear vs macrocyclic).

The regulatory environment is also mixed. At the end of 2017, the European Medicines Agency suspended marketing authorization for all linear GBCAs with the exception of Eovist (gadoxetate disodium) and MultiHance (gadobenate dimeglumine), which can still be used for liver scans because these agents are taken up in the liver and meet an important diagnostic need. Conversely in the United States, the ACR, the American Society of Neuroradiology, and the FDA have recently reviewed and upheld the value of both linear and macrocyclic agents for detecting disease and monitoring response to treatment.

“GBCAs provide crucial, life-saving medical information. Each time a gadolinium-enhanced MRI study is considered, it would be prudent to consider the clinical benefit of the diagnostic information or treatment result that MRI or MRA may provide against the unknown potential risk of gadolinium deposition in the brain for each individual patient. Particular attention should be paid to pediatric and other patients who may receive many GBCA-enhanced MRI studies over the course of their lifetimes. If the decision for an individual patient is made to use a GBCA for an MRI study, multiple factors need to be considered when selecting a GBCA, including diagnostic efficacy, relaxivity, rate of adverse reactions, dosing/concentration, and propensity to deposit in more sensitive organs such as the brain. As this gadolinium deposition phenomenon remains a relatively undefined clinical phenomenon, and accurate and complete data may be useful as investigations proceed, the identity and dose of GBCA used should be recorded after each intravenous administration.”

**vi. High-risk Populations**

a. **Age >60 Years**
   
   It is recommended and important to obtain current eGFR values before administering GBCAs to patients >60 years old.

b. **Renal Impairment and Proinflammatory Conditions**

   Prior to receiving GBCAs, patients with a history of renal disease, hypertension, or diabetes should have their eGFR checked and compared with previous values to determine whether renal impairment is acute or chronic.

c. **Cardiovascular Disease**

   There are no specific recommendations regarding the use of GBCAs in patients with cardiovascular disease. However, good judgment is recommended. Dose volume and history of gadolinium allergies are important to note.

d. **Implants**

   Standard recommendations for metal and other device implants should be followed.
e. Pregnancy

GBCAs should not be administered during the first and second trimesters of pregnancy; caution should be exercised during the third. A GBCA may enter the amniotic fluid and recirculate rather than being excreted, which increases the exposure duration and, at least in theory, increases the chance of the chelate bond breaking and releasing free gadolinium. Therefore, the ACR recommends avoiding GBCAs during pregnancy unless the exam cannot be performed without contrast, no other options are available, and it is deemed medically necessary.44 If MRI is still indicated in a pregnant patient, noncontrast time-of-flight sequences such as steady-state free precession and single-shot techniques (eg, T2 FSE) can be suggested.

D. Immediate Adverse Events

GBCAs have been used in the vast majority of CE-MRI procedures, have long been considered safe for routine clinical use, and lack the nephrotoxicity associated with a large volume of iodinated contrast media. Although the reported incidence of adverse events varies with MR procedure, study population, study design, and site of study,1–8 few differences have been noted between different agents in terms of incidence or type of adverse event (Table 8).

Table 8. Reported Incidence of Common Adverse Events of FDA-approved GBCAs1–8

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Back pain, %</td>
<td>&lt;1</td>
<td>NA</td>
<td>NA</td>
<td>1.2</td>
<td>NA</td>
<td>NA</td>
<td>0.6</td>
<td>NA</td>
</tr>
<tr>
<td>Blood pressure increased/hypertension, %</td>
<td>&lt;1</td>
<td>NA</td>
<td>NA</td>
<td>&lt;1</td>
<td>NA</td>
<td>NA</td>
<td>0.4</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>Dizziness, %</td>
<td>1</td>
<td>&lt;1</td>
<td>≤3</td>
<td>3.7</td>
<td>0.5</td>
<td>0.5</td>
<td>0.6</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>Feeling cold, %</td>
<td>&lt;1</td>
<td>NA</td>
<td>NA</td>
<td>≤0.1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>Feeling hot, %</td>
<td>&lt;1</td>
<td>NA</td>
<td>≤1</td>
<td>NA</td>
<td>0.4</td>
<td>1.0</td>
<td>0.8</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>Headache, %</td>
<td>4.8</td>
<td>&lt;1</td>
<td>≤3</td>
<td>9.4</td>
<td>1.5</td>
<td>1.2</td>
<td>1.1</td>
<td>0.4</td>
</tr>
<tr>
<td>Injection site reaction, %</td>
<td>2.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>≤1</td>
<td>≤1</td>
<td>1.5</td>
<td>0.4</td>
<td>1.1</td>
<td>0.4</td>
<td>-&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Nausea, %</td>
<td>2.7</td>
<td>1.4</td>
<td>≤3</td>
<td>3.2</td>
<td>1.1</td>
<td>1.3</td>
<td>1.1</td>
<td>0.6</td>
</tr>
<tr>
<td>Paresthesia, %</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>≤1</td>
<td>2.2</td>
<td>0.1</td>
<td>0.5</td>
<td>0.3</td>
<td>&lt;0.2&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>Pruritus, %</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>≤1</td>
<td>&lt;1</td>
<td>0.2</td>
<td>&lt;0.5</td>
<td>0.3</td>
<td>&lt;0.2</td>
</tr>
<tr>
<td>Rash, %</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>≤1</td>
<td>&lt;1</td>
<td>0.3</td>
<td>&lt;0.5</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>Taste perversion/dysgeusia, %</td>
<td>&lt;1</td>
<td>1.4</td>
<td>≤1</td>
<td>6.2</td>
<td>0.4</td>
<td>0.7</td>
<td>0.4</td>
<td>≤0.2</td>
</tr>
<tr>
<td>Urticaria, %</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>≤1</td>
<td>&lt;1</td>
<td>0.1</td>
<td>&lt;0.5</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Vasodilatation, %</td>
<td>&lt;1</td>
<td>NA</td>
<td>≤1</td>
<td>6.4</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Vomiting, %</td>
<td>&lt;1</td>
<td>&lt;1</td>
<td>≤1</td>
<td>&lt;1</td>
<td>0.4</td>
<td>&lt;0.5</td>
<td>0.4</td>
<td>≤0.2</td>
</tr>
</tbody>
</table>

FDA = US Food and Drug Administration; GBCAs = gadolinium-based contrast agents; NA = not available.
<sup>a</sup>Injection site coldness/localized coldness.
<sup>b</sup>Injection site reactions reported separately, as follows: injection site pain (0.4%) and injections site coldness (0.2%).
<sup>c</sup>Burning sensation reported separately (<0.2%).
• **Mild reactions** are generally those considered self-limiting, such as headache, nausea, taste perversion, and urticaria (hives) with mild pruritus. The ACR recommends reassuring patients who experience these symptoms and observing them to ensure that the reaction does not evolve into a more severe event.  

• **Moderate reactions** involve tachycardia or bradycardia, hypertension, bronchospasm, and laryngeal swelling. Any moderate reaction calls for immediate treatment and continued observation to prevent it from developing into a life-threatening event.  

• **Severe reactions:** Patients have experienced rare anaphylactoid and anaphylactic reactions after every GBCA; therefore, personnel trained in contrast reaction recognition and management should be readily available when gadolinium is administered.

### i. Treating Reactions to Contrast Agents

Certain medications and equipment must be available to treat reactions, including partial nonrebreather oxygen masks, valve and mouth masks, oxygen, flow valve, nasal prongs, tubing, suction (wall mounted or portable with tubing and catheters), oral airways, stethoscopes, sphygmomanometer, tourniquet, tongue depressor, tracheostomy set, and endotracheal tubes and laryngoscopes. In addition, epinephrine, antihistamine, atropine, β-agonist inhaler, nitroglycerin, aspirin, and fluids should be on hand.

The ACR recommends all patients who experience a reaction should be monitored for 20 to 30 minutes after the injection of a GBCA to ensure complete recovery from symptoms. However, as mentioned above, the monitoring times recommended in the prescribing information vary for the different GBCAs; specifically, closely monitoring patients for hypersensitivity reactions is recommended during administration and, where specified, from up to 2 hours (MultiHance [gadobenate dimeglumine]) to up to several hours (Magnevist [gadopentetate dimeglumine], ProHance [gadoteridol], Omniscan [gadodiamide], OptiMARK [gadoversetamide]) following contrast administration. The ACR also recommends premedicating at-risk patients with corticosteroids and antihistamines, when appropriate, and closely monitoring patients with a history of asthma, allergic respiratory disorder, or previous reaction to GBCA or iodinated contrast agents. Hydration is important for all patients, particularly those with renal insufficiency or paraproteinemias, and for neonates, the elderly, and debilitated individuals who may be compromised by dehydration.

#### a. Contrast Extravasation

- Initial treatment includes
  - Elevation of the affected extremity above the heart
  - Application of cold packs or warm compresses
  - Observation
  - Consultation with the referring physician or surgeon for severe extravasation injury

#### b. Immediate Type Reactions

- Oxygen
- Antiemetics for nausea and vomiting
- Antihistamines for symptomatic urticaria, angioedema, or diffuse erythema
- β-Agonist for bronchospasm
- Leg elevation
- Fluid therapy

#### c. NSF

There is presently no treatment for NSF. Plasmapheresis, a process by which plasma is removed from the blood by a device called a cell separator, has demonstrated some success. Physical and ultraviolet therapies, corticosteroids, and photopheresis have also been associated with anecdotal success.
2. MR SAFETY

In general, MR imaging is considered to be a relatively safe diagnostic modality. The risks inherent in clinical MR imaging have long been understood and have not significantly changed, even as increasing numbers of exams are performed at higher magnetic field strength (eg, 3T). The principal hazards associated with any static magnetic field are projectile effects if ferromagnetic materials are inadvertently brought in close proximity to the MR system, and the possibility of metallic implants experiencing substantial magnetic field interactions and moving internally due to forces induced by the external magnetic field. Both of these effects are potentially a greater concern as the static magnetic field strength of the MR system increases.

Other hazards exist as well. Radiofrequency (RF) energy transmitted into patients (excitation pulses) may cause the tissues of the body to heat up. Because certain pulse sequences cause more heating than others, the FDA has provided guidance on the rate of RF energy deposition, termed specific absorption rate (SAR), which is permissible. SAR limitations are generally monitored by the software of the MR system so that maximum allowable SAR cannot be reached. SAR limitations become more of a problem at 3T because SAR increases with the square of the magnetic field.

MR systems require the use of RF pulses to create the MR signal. This RF energy is transmitted readily through free space from the transmit RF coil to the patient. However, the use of RF coils, physiologic monitors, electronically activated devices, and external accessories or objects made from conductive materials may cause excessive heating, resulting in burn injuries to patients undergoing MR procedures. The nature of high-frequency electromagnetic fields is such that the energy can be transmitted across open space and through insulators. Therefore, only devices with carefully designed current paths can be made safe for use during MR procedures. Simply insulating conductive material (eg, wire or lead) or separating it from the patient may not be sufficient to prevent excessive heating or burns from occurring. Heating of implants and similar devices may also occur in association with MR procedures, but this tends to be problematic primarily for objects made from conductive materials that have elongated shapes, such as leads, guidewires, and certain types of catheters (eg, catheters with thermistors or other conducting components).

Furthermore, certain geometrical shapes exhibit the phenomenon of “resonance,” which increases their propensity to concentrate RF currents. At the operating frequencies of present-day MR systems, conducting loops of tens of centimeters in size may create problems and, therefore, must be avoided, unless high impedance is used to limit RF current. Importantly, even loops that include small gaps separated by insulation may still conduct current.

Notably, many incidents of excessive heating have been reported in patients undergoing MR procedures in the United States that were unrelated to equipment problems or the presence of conductive external or internal implants or materials. These incidents included first-, second-, and third-degree burns that were experienced by patients. In many of these cases, the reports indicated that the limbs or other body parts of the patients were in direct contact with body RF coils or other transmit RF coils of the MR systems or there were skin-to-skin contact points suspected of being responsible for these injuries.

To prevent patients from experiencing excessive heating and possible burns in association with MR procedures, the following guidelines are recommended:

- Prepare the patient for the MR procedure by ensuring that there are no unnecessary metallic objects contacting the patient's skin (eg, metallic drug delivery patches, jewelry, necklaces, bracelets, key chains)
• Prepare the patient for the MR procedure by using insulation material (ie, appropriate padding) to prevent skin-to-skin contact points and the formation of “closed loops” from touching body parts.

• Insulating material (minimum recommended thickness, 1 cm) should be placed between the patient’s skin and the transmit RF coil that is used for the MR procedure (alternatively, the RF coil itself can be padded). For example, position the patient so there is no direct contact between the patient’s skin and the body RF coil of the MR system. This may be accomplished by having the patient place his/her arms over his/her head or by using elbow pads or foam padding between the patient’s tissue and the body RF coil of the MR system. This is especially important for MR examinations that use the body coil or other large RF coils for transmission of RF energy.

• Use only electrically conductive devices, equipment, accessories (eg, ECG leads and electrodes), and materials that have been thoroughly tested and determined to be safe and compatible for MR procedures.

• Carefully follow specific MR safety criteria and recommendations for implants made from electrically conductive materials (eg, bone fusion stimulators and neurostimulation systems).

• Before using electrical equipment, check the integrity of the insulation and/or housing of all components, including surface RF coils, monitoring leads, cables, and wires. Preventive maintenance should be practiced routinely for such equipment.

• Remove all nonessential electrically conductive materials from the MR system (unused surface RF coils, ECG leads, cables, wires, etc).

• Keep electrically conductive materials that must remain in the MR system from directly contacting the patient by placing thermal and/or electrical insulation between the conductive material and the patient.

• Keep electrically conductive materials that must remain within the body RF coil or other transmit RF coil of the MR system from forming conductive loops. **Note:** The patient’s tissue is conductive and, therefore, may be involved in the formation of a conductive loop, which can be circular, U-shaped, or S-shaped.

• Position electrically conductive materials to prevent “cross points.” For example, a cross point is the point where a cable crosses another cable, where a cable loops across itself, or where a cable touches either the patient or the sides of the transmit RF coil more than once. Notably, even the close proximity of conductive materials with each other should be avoided because some cables and RF coils can capacitively couple (without any contact or crossover) when placed close together.

• Position electrically conductive materials to exit down the center of the MR system (ie, not along the side of the MR system or close to the body RF coil or other transmit RF coil).

• Do not position electrically conductive materials across an external metallic prosthesis (eg, external fixation device or cervical fixation device) or similar device that is in direct contact with the patient.

• Allow only properly trained individuals to operate devices (eg, monitoring equipment) in the MR environment.

• Follow all manufacturer instructions for the proper operation and maintenance of physiologic monitoring or other similar electronic equipment intended for use during MR procedures.

• Electrical devices that do not appear to be operating properly during the MR procedure should be removed from the patient immediately.

• Closely monitor the patient during the MR procedure. If the patient reports sensations of heating or other unusual sensations, discontinue the MR procedure immediately and perform a thorough assessment of the situation.

• RF surface coil decoupling failures can cause localized RF power deposition levels to reach excessive levels. The MR system operator will recognize such a failure as a set of concentric semicircles in the tissue on the associated MR image or as an unusual amount of image nonuniformity related to the position of the RF coil.
• Administering contrast material as part of the MR exam increases risk, including the possibility of contrast extravasation during the administration process and adverse drug reactions. It is therefore of the utmost importance to identify patients at particular risk and use the lowest possible dose necessary to achieve the needed diagnostic accuracy.

3. PATIENT SCREENING

To minimize MRI-associated incidents and accidents, it is important that personnel are provided up-to-date, accurate safety information on a regular basis. Information is evolving, and new areas of interest include the safe use of GBCAs in patients with renal dysfunction in light of NSF and evaluation of items such as implants and devices as MRI-compatible, including at 3T.

Certain aspects of patient screening for MR procedures are best carried out during the scheduling process. These activities should be conducted by a healthcare worker specifically trained in MR safety (ie, an individual who is trained to understand the potential hazards and issues associated with the MR environment and procedures and who is sufficiently familiar with the institution’s screening procedures). In scheduling the patient, it should be determined whether the patient has an implant that may be contraindicated or requires special attention during the MR procedure (eg, a ferromagnetic aneurysm clip, pacemaker, or neurostimulation system), and whether there is a physical condition that needs careful consideration (eg, the patient is pregnant, has a disability, or has a metallic foreign body). One condition that should be carefully considered before a patient undergoes an MR procedure is renal failure. Patients should be asked if they have a history of renal dysfunction or if they are taking nephrotoxic medications. Patients with suspected renal dysfunction should have their blood urea nitrogen and serum creatinine levels tested or their eGFR calculated. In addition, in this subset of patients, the ACR recommends obtaining an eGFR within 6 weeks of GBCA administration.

Preliminary screening helps to prevent scheduling patients who are inappropriate candidates for MR examinations. Following preliminary screening, the patient should undergo comprehensive screening in the MR department. This should involve the use of a printed screening form to document the screening procedure, a review of the information on the screening form, and a verbal conversation verifying the information and giving the patient an opportunity to address his or her concerns. An MR-safety trained healthcare professional must conduct this aspect of patient screening. An example of such a form can be found at www.MRIsafety.com.

4. CONCLUSIONS

The application of GBCAs in MR imaging has improved the ability of radiologists to detect and characterize pathological processes within the human body. While these agents and MR imaging overall are considered extremely safe, proper patient screening is paramount, particularly screening for renal dysfunction to minimize the possibility of a patient developing NSF.

MR imaging procedures should, in general, be avoided in pregnant patients and patients with pacemakers and implantable cardioverter defibrillators, unless determined by an MR-safety specialist (ie, a radiologist or cardiologist) to be absolutely necessary and performed in accordance with highly specific safety precautions. The GBCAs approved for use in MR imaging in the United States – Magnevist (gadopentetate dimeglumine), ProHance (gadoteridol), Omniscan (gadodiamide), OptiMARK (gadoversetamide), MultiHance (gadobenate dimeglumine), Eovist (gadoxetate disodium), Gadavist (gadobutrol), and Dotarem (gadoterate meglumine) – have similar immediate adverse event profiles.
and are safe for use in most individuals. However, they should be used with extreme caution in patients with a prior adverse reaction to contrast media (including GBCAs and iodinated contrast agents), those with respiratory disorders such as asthma, and those with impaired renal function.

GBCAs have been associated with the development of NSF in renally impaired patients, and steps should be taken to minimize the risk for this condition in these individuals, including initiating a comprehensive patient screening process, administering as low a dose of a GBCA as possible, selecting an appropriate GBCA, and, when appropriate, performing hemodialysis in patients who have renal insufficiency as soon as possible after the MR exam. Repeated administration of GBCAs has also recently been associated with gadolinium retention in the brain, causing residual brightness in the globus pallidus and the dentate nucleus of some patients. To date, no adverse clinical consequences of gadolinium retention have been demonstrated, and research is ongoing to ensure optimum patient safety.
5. REFERENCES

2. ProHance (gadoteridol) injection, 279.3 mg/mL [prescribing information]. Monroe Township, NJ: Bracco Diagnostics Inc.; January 2018.


